HIV Negative and HIV Prevention

 

 Give PrEP a Shot (HPTN 083)

Assessing the safety and efficacy of cabotegravir, an investigational, long-acting, injectable HIV medication, versus Truvada, the only FDA-approved medication for HIV prevention. Participants are randomized 1:1 to receive active cabotegravir or Truvada and an appropriate matching placebo. During the first step of the study, participants take oral cabotegravir or oral Truvada for five weeks; in the second step, participants continue oral Truvada (or placebo) and begin receiving gluteal injections of cabotegravir (or placebo) every eight weeks for up to 3.5 years. In step three, all participants receive open-label Truvada for one year to prevent HIV infection while residual cabotegravir levels slowly dissipate over time.
Population: MSM, transgender women (born male)
Location: Chapel Hill / Greensboro
Duration: Up to 4.5 years
Contact: Becky Straub, RN, 919-843-9975 or Miriam Chicurel-Bayard, RN, 919-843-9922
WEB: Fill out our contact form for this and other prevention studies

(same as above) HPTN 083: A phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumerate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis In HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

HPTN 087

Evaluating the safety, tolerability, and serum concentrations of VRC-HIVMAB075-00-AB (VRC07-523LS), a human monoclonal antibody being tested for possible use in HIV prevention. Participants will be randomized into 1 of 5 arms, receiving up to 5 IV infusions or subcutaneous injections. This is a multicenter, randomized phase 1 clinical trial and will last for 3.5 years.

Population: MSM, transgender women (born male)
Locations: Chapel Hill
Duration: 3.5 years
Contact: Maureen Furlong, RN, 919-966-8524 or Becky Straub, RN, 919-843-9975
WEB: Fill out our contact form for this and other prevention studies

(same as above) HVTN 127/HPTN 087: A multicenter, randomized phase 1 clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses, routes, and dosing schedules to healthy, HIV-uninfected adults.

CID 0702: Apheresis procedures to obtain leukocytes from HIV negative subjects

Q:Samples used as a negative control for exploring new methods of activating resting HIV infected cells in laboratory
POP: must be HIV negative and > 18 years of age
DUR: up to 3 years
CALL: Francesca Prince, 919-966-8794 or 919-428-7612 or Caroline Baker, 919-966-2623